Accuray Incorporated (ARAY) 5.42 $ARAY
Accuray (ARAY) Q4 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:44AM CDT
Shares of Accuray witnessed a 13.2% plunge in after-hours trading following the company???s fourth-quarter fiscal 2016 results.
MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Accuray Reports Fourth Quarter and Fiscal 2016 Financial Results
PR Newswire - Wed Aug 17, 3:01PM CDT
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2016.
ARAY: 5.42 (+0.12)
Accuray Expands Product Portfolio, Radixact Now CE-Marked
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 10:36AM CDT
Accuray Inc (ARAY) is expanding its product portfolio on the back of regulatory approvals.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39)
Accuray CE Marks Its New Radixact(TM) System
PR Newswire Europe - Tue Aug 09, 5:30AM CDT
SUNNYVALE, California, August 9, 2016 /PRNewswire/ --
ARAY: 5.42 (+0.12)
New Data Show InCise(TM) Multileaf Collimator for the CyberKnife® M6(TM) System may Expand Patient Population Eligible for Precise Radiation Treatments
PR Newswire - Thu Aug 04, 5:35AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that more than 45 studies on the use of the CyberKnife® System were presented during poster and oral sessions at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Washington, DC, July 31 - August 4, 2016. The CyberKnife System is the only stereotactic body radiation therapy (SBRT) system capable of tracking and automatically correcting for target motion in real time, even while the tumor moves. The System's sub-millimeter accuracy enables clinicians to effectively treat tumors while preserving healthy tissue.
ARAY: 5.42 (+0.12)
New Data Demonstrating TomoTherapy® System Adaptive Capabilities and Workhorse Reliability Presented at Leading Scientific Meeting for Medical Physicists
PR Newswire - Thu Aug 04, 5:30AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that new studies demonstrating the TomoTherapy® System's leading-edge adaptive therapy capabilities and value as a mainstream radiation therapy device were presented at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Washington, DC, July 31 - August 4, 2016. More than 35 studies evaluating the system were shared during poster and oral presentations. The TomoTherapy System is used worldwide to treat a wide range of cancer cases, from the routine to complex, with extreme precision.
ARAY: 5.42 (+0.12)
Accuray Retires Remaining 3.75% Convertible Debt
PR Newswire - Tue Aug 02, 5:30AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today the Company has settled the remaining principal amount and accrued interest thereon of the 3.75% Convertible Senior Notes (the "2016 Notes"
. The 2016 Notes were settled on August 1, 2016 for cash of $37.3 million, which included $36.6 million in principal and $0.7 million in accrued interest.
ARAY: 5.42 (+0.12)
Accuray's (ARAY) TomoTherapy System Uptake on the Rise
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:00AM CDT
Accuray Inc.'s (ARAY) TomoTherapy System continues to gain traction in international markets.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39)
Accuray Wins 7 TomoTherapy Orders from NHS, Stock Up
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:15AM CDT
Accuray (ARAY) recently won seven TomoTherapy System orders from NHS Supply Chain in the U.K.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39)
United Kingdom's NHS Supply Chain to Acquire Seven TomoTherapy® Systems
PR Newswire Europe - Thu Jun 16, 5:31AM CDT
SUNNYVALE, California, June 16, 2016 /PRNewswire/ --
ARAY: 5.42 (+0.12)
How Rewarding Investors Believe These Medical Appliances and Equipment Stocks are? - Edwards Lifesciences, Stryker, Accuray, and ABIOMED
PR Newswire - Wed Jun 08, 7:55AM CDT
Increasing demands for new developments are driving up growth in the Medical Appliances and Equipment space, one of the biggest industries in the U.S. Healthcare sector. ActiveWallSt.com has lined the following stocks for investors' assessment: Edwards Lifesciences Corp. (NYSE: EW), Stryker Corp. (NYSE: SYK), Accuray Inc. (NASDAQ: ARAY), and ABIOMED Inc. (NASDAQ: ABMD). Access these stocks complimentary alerts at:
ABMD: 117.43 (-0.20), EW: 115.85 (-0.02), ARAY: 5.42 (+0.12), SYK: 115.60 (+0.37)
Accuray to Participate in the 2016 Jefferies Healthcare Conference
PR Newswire - Wed May 25, 6:00AM CDT
Accuray Incorporated (NASDAQ: ARAY), announced today that Joshua H. Levine, President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference in New York, NY on Friday, June 10, 2016 at 8:00 a.m. ET.
ARAY: 5.42 (+0.12)
Accuray to Host Analyst and Investor Day on May 20, 2016
PR Newswire - Thu May 19, 6:00AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Analyst and Investor Day on Friday, May 20, 2016 at the Lotte Palace Hotel in New York City.
ARAY: 5.42 (+0.12)
Accuray Signs Long-Term Strategic Development and Supply Agreement with medPhoton for Volumetric Image Guidance Solutions for the CyberKnife® System
PR Newswire - Sun May 01, 10:55PM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that the company has signed an agreement with medPhoton GmbH to collaborate on integration of its ImagingRing® system, a new technology for volumetric image guidance, with the CyberKnife® System. The ImagingRing provides a range of advanced imaging capabilities including large field-of-view cone beam CT. This long-term strategic agreement will provide Accuray with certain exclusive development, sales and distribution rights of the unique ImagingRing for use in adaptive radiation therapy, SBRT and robotic radiosurgery.
ARAY: 5.42 (+0.12)
Accuray to Unveil Latest Innovations at Estro
PR Newswire Europe - Thu Apr 28, 2:02AM CDT
SUNNYVALE, California, April 28, 2016 /PRNewswire/ --
ARAY: 5.42 (+0.12)
Accuray (ARAY) Posts Earnings in Q3, Down on View Cut
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:55AM CDT
Shares of Accuray Inc. (ARAY) fell 3.3% in after-hours trading following the company's third-quarter fiscal 2016 results and trimmed fiscal 2016 guidance.
INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10), ARAY: 5.42 (+0.12), HOLX: 38.51 (+0.05)
Accuray beats 3Q profit forecasts
Automated Insights - Tue Apr 26, 4:05PM CDT
SUNNYVALE, Calif. (AP) _ Accuray Inc. (ARAY) on Tuesday reported fiscal third-quarter net income of $756,000, after reporting a loss in the same period a year earlier.
ARAY: 5.42 (+0.12)
Accuray Submits 510(k) Premarket Notification to FDA for Its Radixact(TM) Treatment Delivery System
PR Newswire - Tue Apr 26, 3:05PM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today the submission of its 510(k) premarket notification with the Food and Drug Administration (FDA) for the company's Radixact(TM) Treatment Delivery System. Accuray also submitted 510(k) premarket notification for its treatment planning and data management systems, Precision(TM) Treatment Planning System and iDMS(TM) Data Management System.
ARAY: 5.42 (+0.12)
Accuray (ARAY) Q4 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:44AM CDT
Shares of Accuray witnessed a 13.2% plunge in after-hours trading following the company???s fourth-quarter fiscal 2016 results.
MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39), NUVA: 66.74 (+0.68)
Accuray Reports Fourth Quarter and Fiscal 2016 Financial Results
PR Newswire - Wed Aug 17, 3:01PM CDT
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2016.
ARAY: 5.42 (+0.12)
Accuray Expands Product Portfolio, Radixact Now CE-Marked
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 10:36AM CDT
Accuray Inc (ARAY) is expanding its product portfolio on the back of regulatory approvals.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39)
Accuray CE Marks Its New Radixact(TM) System
PR Newswire Europe - Tue Aug 09, 5:30AM CDT
SUNNYVALE, California, August 9, 2016 /PRNewswire/ --
ARAY: 5.42 (+0.12)
New Data Show InCise(TM) Multileaf Collimator for the CyberKnife® M6(TM) System may Expand Patient Population Eligible for Precise Radiation Treatments
PR Newswire - Thu Aug 04, 5:35AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that more than 45 studies on the use of the CyberKnife® System were presented during poster and oral sessions at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Washington, DC, July 31 - August 4, 2016. The CyberKnife System is the only stereotactic body radiation therapy (SBRT) system capable of tracking and automatically correcting for target motion in real time, even while the tumor moves. The System's sub-millimeter accuracy enables clinicians to effectively treat tumors while preserving healthy tissue.
ARAY: 5.42 (+0.12)
New Data Demonstrating TomoTherapy® System Adaptive Capabilities and Workhorse Reliability Presented at Leading Scientific Meeting for Medical Physicists
PR Newswire - Thu Aug 04, 5:30AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that new studies demonstrating the TomoTherapy® System's leading-edge adaptive therapy capabilities and value as a mainstream radiation therapy device were presented at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Washington, DC, July 31 - August 4, 2016. More than 35 studies evaluating the system were shared during poster and oral presentations. The TomoTherapy System is used worldwide to treat a wide range of cancer cases, from the routine to complex, with extreme precision.
ARAY: 5.42 (+0.12)
Accuray Retires Remaining 3.75% Convertible Debt
PR Newswire - Tue Aug 02, 5:30AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today the Company has settled the remaining principal amount and accrued interest thereon of the 3.75% Convertible Senior Notes (the "2016 Notes"
. The 2016 Notes were settled on August 1, 2016 for cash of $37.3 million, which included $36.6 million in principal and $0.7 million in accrued interest. ARAY: 5.42 (+0.12)
Accuray's (ARAY) TomoTherapy System Uptake on the Rise
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 9:00AM CDT
Accuray Inc.'s (ARAY) TomoTherapy System continues to gain traction in international markets.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39)
Accuray Wins 7 TomoTherapy Orders from NHS, Stock Up
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:15AM CDT
Accuray (ARAY) recently won seven TomoTherapy System orders from NHS Supply Chain in the U.K.
IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), ARAY: 5.42 (+0.12), CRY: 16.23 (+0.39)
United Kingdom's NHS Supply Chain to Acquire Seven TomoTherapy® Systems
PR Newswire Europe - Thu Jun 16, 5:31AM CDT
SUNNYVALE, California, June 16, 2016 /PRNewswire/ --
ARAY: 5.42 (+0.12)
How Rewarding Investors Believe These Medical Appliances and Equipment Stocks are? - Edwards Lifesciences, Stryker, Accuray, and ABIOMED
PR Newswire - Wed Jun 08, 7:55AM CDT
Increasing demands for new developments are driving up growth in the Medical Appliances and Equipment space, one of the biggest industries in the U.S. Healthcare sector. ActiveWallSt.com has lined the following stocks for investors' assessment: Edwards Lifesciences Corp. (NYSE: EW), Stryker Corp. (NYSE: SYK), Accuray Inc. (NASDAQ: ARAY), and ABIOMED Inc. (NASDAQ: ABMD). Access these stocks complimentary alerts at:
ABMD: 117.43 (-0.20), EW: 115.85 (-0.02), ARAY: 5.42 (+0.12), SYK: 115.60 (+0.37)
Accuray to Participate in the 2016 Jefferies Healthcare Conference
PR Newswire - Wed May 25, 6:00AM CDT
Accuray Incorporated (NASDAQ: ARAY), announced today that Joshua H. Levine, President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference in New York, NY on Friday, June 10, 2016 at 8:00 a.m. ET.
ARAY: 5.42 (+0.12)
Accuray to Host Analyst and Investor Day on May 20, 2016
PR Newswire - Thu May 19, 6:00AM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Analyst and Investor Day on Friday, May 20, 2016 at the Lotte Palace Hotel in New York City.
ARAY: 5.42 (+0.12)
Accuray Signs Long-Term Strategic Development and Supply Agreement with medPhoton for Volumetric Image Guidance Solutions for the CyberKnife® System
PR Newswire - Sun May 01, 10:55PM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today that the company has signed an agreement with medPhoton GmbH to collaborate on integration of its ImagingRing® system, a new technology for volumetric image guidance, with the CyberKnife® System. The ImagingRing provides a range of advanced imaging capabilities including large field-of-view cone beam CT. This long-term strategic agreement will provide Accuray with certain exclusive development, sales and distribution rights of the unique ImagingRing for use in adaptive radiation therapy, SBRT and robotic radiosurgery.
ARAY: 5.42 (+0.12)
Accuray to Unveil Latest Innovations at Estro
PR Newswire Europe - Thu Apr 28, 2:02AM CDT
SUNNYVALE, California, April 28, 2016 /PRNewswire/ --
ARAY: 5.42 (+0.12)
Accuray (ARAY) Posts Earnings in Q3, Down on View Cut
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 10:55AM CDT
Shares of Accuray Inc. (ARAY) fell 3.3% in after-hours trading following the company's third-quarter fiscal 2016 results and trimmed fiscal 2016 guidance.
INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10), ARAY: 5.42 (+0.12), HOLX: 38.51 (+0.05)
Accuray beats 3Q profit forecasts
Automated Insights - Tue Apr 26, 4:05PM CDT
SUNNYVALE, Calif. (AP) _ Accuray Inc. (ARAY) on Tuesday reported fiscal third-quarter net income of $756,000, after reporting a loss in the same period a year earlier.
ARAY: 5.42 (+0.12)
Accuray Submits 510(k) Premarket Notification to FDA for Its Radixact(TM) Treatment Delivery System
PR Newswire - Tue Apr 26, 3:05PM CDT
Accuray Incorporated (NASDAQ: ARAY) announced today the submission of its 510(k) premarket notification with the Food and Drug Administration (FDA) for the company's Radixact(TM) Treatment Delivery System. Accuray also submitted 510(k) premarket notification for its treatment planning and data management systems, Precision(TM) Treatment Planning System and iDMS(TM) Data Management System.
ARAY: 5.42 (+0.12)
